Literature DB >> 34611829

Polysaccharide Krestin Prevents Alzheimer's Disease-type Pathology and Cognitive Deficits by Enhancing Monocyte Amyloid-β Processing.

Si-Han Chen1,2,3,4, Chen-Yang He1,2,3, Ying-Ying Shen1,2,3, Gui-Hua Zeng1,2,3, Ding-Yuan Tian1,2,3, Yuan Cheng1,2,3, Man-Yu Xu1,2,3, Dong-Yu Fan1,2,3, Cheng-Rong Tan1,2,3, An-Yu Shi1,2,3, Xian-Le Bu5,6,7,8, Yan-Jiang Wang9,10,11,12,13.   

Abstract

Deficits in the clearance of amyloid β protein (Aβ) by the peripheral system play a critical role in the pathogenesis of sporadic Alzheimer's disease (AD). Impaired uptake of Aβ by dysfunctional monocytes is deemed to be one of the major mechanisms underlying deficient peripheral Aβ clearance in AD. In the current study, flow cytometry and biochemical and behavioral techniques were applied to investigate the effects of polysaccharide krestin (PSK) on AD-related pathology in vitro and in vivo. We found that PSK, widely used in therapy for various cancers, has the potential to enhance Aβ uptake and intracellular processing by human monocytes in vitro. After administration of PSK by intraperitoneal injection, APP/PS1 mice performed better in behavioral tests, along with reduced Aβ deposition, neuroinflammation, neuronal loss, and tau hyperphosphorylation. These results suggest that PSK holds promise as a preventive agent for AD by strengthening the Aβ clearance by blood monocytes and alleviating AD-like pathology.
© 2021. Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences.

Entities:  

Keywords:  Alzheimer’s disease; Aβ uptake; Monocyte; Polysaccharide krestin

Mesh:

Substances:

Year:  2021        PMID: 34611829      PMCID: PMC8975919          DOI: 10.1007/s12264-021-00779-5

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN: 1995-8218            Impact factor:   5.203


  35 in total

1.  Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficits.

Authors:  Shu-Sheng Jiao; Xiu-Qing Yao; Yu-Hui Liu; Qing-Hua Wang; Fan Zeng; Jian-Jun Lu; Jia Liu; Chi Zhu; Lin-Lin Shen; Cheng-Hui Liu; Ye-Ran Wang; Gui-Hua Zeng; Ankit Parikh; Jia Chen; Chun-Rong Liang; Yang Xiang; Xian-Le Bu; Juan Deng; Jing Li; Juan Xu; Yue-Qin Zeng; Xiang Xu; Hai-Wei Xu; Jin-Hua Zhong; Hua-Dong Zhou; Xin-Fu Zhou; Yan-Jiang Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

2.  Role of toll-like receptor signalling in Abeta uptake and clearance.

Authors:  Kazuki Tahara; Hong-Duck Kim; Jing-Ji Jin; J Adam Maxwell; Ling Li; Ken-ichiro Fukuchi
Journal:  Brain       Date:  2006-09-19       Impact factor: 13.501

3.  Imaging flow cytometry in the assessment of leukocyte-platelet aggregates.

Authors:  Henry Hui; Kathy A Fuller; Wendy N Erber; Matthew D Linden
Journal:  Methods       Date:  2016-10-05       Impact factor: 3.608

4.  CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation.

Authors:  Erin G Reed-Geaghan; Julie C Savage; Amy G Hise; Gary E Landreth
Journal:  J Neurosci       Date:  2009-09-23       Impact factor: 6.167

5.  Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling.

Authors:  Hisham Qosa; Bilal S Abuasal; Ignacio A Romero; Babette Weksler; Pierre-Oliver Couraud; Jeffrey N Keller; Amal Kaddoumi
Journal:  Neuropharmacology       Date:  2014-01-24       Impact factor: 5.250

6.  Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9.

Authors:  Maya Koronyo-Hamaoui; Minhee K Ko; Yosef Koronyo; David Azoulay; Akop Seksenyan; Gilad Kunis; Michael Pham; Joshua Bakhsheshian; Patricia Rogeri; Keith L Black; Daniel L Farkas; Michal Schwartz
Journal:  J Neurochem       Date:  2009-09-24       Impact factor: 5.372

Review 7.  Toll-like receptors in Alzheimer's disease: a therapeutic perspective.

Authors:  Maria E Gambuzza; Vincenza Sofo; Francesca M Salmeri; Luca Soraci; Silvia Marino; Placido Bramanti
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

8.  Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model.

Authors:  Oleg Butovsky; Gilad Kunis; Maya Koronyo-Hamaoui; Michal Schwartz
Journal:  Eur J Neurosci       Date:  2007-07-10       Impact factor: 3.386

9.  Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline.

Authors:  Juan Lantero Rodriguez; Thomas K Karikari; Kaj Blennow; Nicholas J Ashton; Marc Suárez-Calvet; Claire Troakes; Andrew King; Andreja Emersic; Dag Aarsland; Abdul Hye; Henrik Zetterberg
Journal:  Acta Neuropathol       Date:  2020-07-27       Impact factor: 17.088

10.  Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer's disease.

Authors:  Yang Xiang; Xian-Le Bu; Yu-Hui Liu; Chi Zhu; Lin-Lin Shen; Shu-Sheng Jiao; Xiao-Yan Zhu; Brian Giunta; Jun Tan; Wei-Hong Song; Hua-Dong Zhou; Xin-Fu Zhou; Yan-Jiang Wang
Journal:  Acta Neuropathol       Date:  2015-09-12       Impact factor: 17.088

View more
  1 in total

1.  Physiological clearance of Aβ by spleen and splenectomy aggravates Alzheimer-type pathogenesis.

Authors:  Zhong-Yuan Yu; Dong-Wan Chen; Cheng-Rong Tan; Gui-Hua Zeng; Chen-Yang He; Jun Wang; Xian-Le Bu; Yan-Jiang Wang
Journal:  Aging Cell       Date:  2021-12-23       Impact factor: 9.304

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.